我要投票 大清生物Datsing在医疗器械行业中的票数:127
· 外 推 电 报 ·
2025-02-23 12:30:51 星期日

【大清生物Datsing是哪个国家的品牌?】

大清生物Datsing是什么牌子?「大清生物Datsing」是 北京大清生物技术股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人 南龙在2001年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力大清生物Datsing品牌出海!通过在本页面挂载大清生物Datsing品牌的产品链接和联系邮箱,可以提高大清生物Datsing产品曝光!跨境电商爆单神器,目前只要100元/年哦~

北京大清生物技术股份有限公司位于中关村科技园核心地区,公司成立于2001年,是由归国留学人员创立的高新技术企业,主要从事生物医学材料、再生医学与组织工程、干细胞与生物治疗产品的研发、生产、销售和服务,是国内较早进行再生医学、组织工程及生物医用材料产品产业化推进的企业之一。2012年底引进北京水木启程创业投资中心作为战略股东,2014年初引进北极光、天津海达创投公司。2006年,大清生物与四川大学华西医院在生物医学材料的研究和产品开发方面达成战略合作伙伴关系。同时依托清华大学生命科学与医学研究院、材料科学与工程研究院、化学工程系以及众多研究机构的技术优势,整合国内外先进技术和资源,在相关技术产业化方面取得多项突破。

大清生物目前有八个产品获得CFDA医疗器械产品注册,分别是:新一代高科技产品可吸收止血膜(大清生物纸)、人造皮肤——基因转染猪皮(贴肤)、同种异体骨修复材料(拜欧金)、同种异体肌腱修复材料(拜欧腱)、生物疝修补片(瑞拜善)、I号牙科种植体、骨修复材料(植骨灵)及牙齿脱敏剂(奥敏清)。目前,公司尚有5个产品在国家指定的临床试验基地开展临床研究或已经完成临床,同时有数个系列产品正在研发中。

大清生物于2003年取得Ⅲ类《医疗器械生产许可证》,2005年通过医疗器械生产企业质量体系考核。2007年通过ISO9001—ISO13485国际质量体系认证。2008年获得国家口腔科材料医疗器械经营许可证。2016年,牙齿脱敏剂产品通过了欧盟CE认证,可吸收止血膜产品通过了CE体系认证。公司在昌平科技园投资建造了4000余平米的先进现代化生产厂房,除生产Ⅱ、Ⅲ类植入医疗器械产品外,还建设了细胞培养室、细胞和支架材料复合产品车间。

为适应企业发展需要,提高企业核心竞争力,公司在中关村医学工程转化中心投资建造了大型研发中心,中心现有研发人员20余名,其中博士2名、硕士10名,高级工程师3名,初步形成了一支多学科有机互补、专业搭配合理的研发队伍。

公司于2012年收购重庆宗申军辉生物技术有限公司(现更名为重庆大清医诚生物技术有限公司)及重庆宗申医达生物技术研发有限公司(现更名为重庆大清医达生物技术有限公司),重庆子公司是专业从事生物医用材料生产的高新技术企业,是典型的“产、学、研”结合体,公司主要产品为基因转染猪皮(贴肤)。

2016年3月收购了北京西格东方医疗电子技术有限公司(现更名为北京大清西格科技有限公司),西格子公司是一家专注数字化口腔产品及服务的供应商,目前公司经销的主要产品有I号种植体、牙齿脱敏剂(奥敏清)、骨粉(拜欧金)等。

2016年9月收购天津中津生物发展有限公司,中津公司是国内较早从事骨活性修复材料生产厂家之一,其主要产品-骨修复材料(植骨灵)为国家专利产品。

大清生物拥有专家、教授、博士和硕士等组成的高科技人才队伍300余人,公司通过建立科学的人力资源考核体系,成立员工持股平台,建立和实施ERP信息管理系统等,树立以人为本的人才观念,打造优秀的企业文化。公司注重员工能力与素质培养,为了提升核心团队的管理能力,2013年、2016年与北京大学光华管理学院合作,特开设EMBA进修一期班、二期班。


英文翻译:Beijing Daqing Biotechnology Co., Ltd. is located in the core area of Zhongguancun Science and technology park. Founded in 2001, it is a high-tech enterprise founded by returned overseas students. It is mainly engaged in the research and development, production, sales and service of biomedical materials, regenerative medicine and tissue engineering, stem cells and biological treatment products. It is the earliest in China to carry out regenerative medicine, tissue engineering and biological treatment One of the enterprises promoting the industrialization of medical material products. At the end of 2012, Beijing Shuimu venture capital center was introduced as the strategic shareholder, and at the beginning of 2014, Beijing Aurora Borealis and Tianjin Haida venture capital company were introduced. In 2006, Daqing biology and West China Hospital of Sichuan University reached a strategic partnership in the research and product development of biomedical materials. At the same time, relying on the technical advantages of the Institute of life science and medicine, the Institute of materials science and engineering, the Department of chemical engineering and many research institutions of Tsinghua University, integrating advanced technologies and resources at home and abroad, we have made many breakthroughs in the industrialization of related technologies. At present, there are eight products of Daqing biology that have obtained CFDA medical device product registration, which are: new generation high-tech product absorbable hemostasis film (Daqing biological paper), artificial skin gene transfected pig skin (skin sticking), allogeneic bone repair material (Bayer gold), allogeneic tendon repair material (Bayer tendon), biological hernia repair sheet (ribeisen), I dental implant , bone repair materials (zhiguling) and tooth desensitizer (aominqing). At present, the company still has 5 products in the national designated clinical trial base to carry out clinical research or have completed clinical research, and several series of products are under development. Daqing biology obtained the class III medical device production license in 2003 and passed the quality system assessment of medical device manufacturers in 2005. In 2007, it passed iso9001-iso13485 international quality system certification. In 2008, it obtained the national stomatological material and medical device business license. In 2016, the tooth desensitizer product passed the EU CE certification, and the absorbable haemostatic film product passed the CE system certification. The company has invested and built more than 4000 square meters of advanced modern production plant in Changping Science and technology park. In addition to producing class II and III implanted medical devices, it has also built cell culture room, cell and scaffold composite product workshop. In order to meet the development needs of the enterprise and improve the core competitiveness of the enterprise, the company has invested and built a large-scale R & D center in Zhongguancun medical engineering transformation center, which has more than 20 R & D personnel, including 2 doctors, 10 masters and 3 senior engineers, and has initially formed a research and development team with multiple disciplines complementing each other organically and reasonable professional collocation. In 2012, the company acquired Chongqing Zongshen Junhui Biotechnology Co., Ltd. (now renamed Chongqing daqingyicheng Biotechnology Co., Ltd.) and Chongqing Zongshen Yida Biotechnology R & D Co., Ltd. (now renamed Chongqing daqingyida Biotechnology Co., Ltd.). Chongqing subsidiary is a high-tech enterprise specializing in the production of biomedical materials and a typical "production, learning and research" The main product of the company is gene transfected pig skin. In March 2016, the company acquired Beijing SiGe Oriental Medical Electronic Technology Co., Ltd. (now renamed Beijing Daqing SiGe Technology Co., Ltd.). Xige company is a supplier focusing on digital oral products and services. At present, the company's main products are no. I implant, tooth desensitizer (aominqing), bone powder (baioujin), etc. In September 2016, Tianjin Zhongjin Biological Development Co., Ltd. was acquired. Zhongjin company is one of the earliest manufacturers of bone active repair materials in China. Its main product bone repair materials (bone graft) is a national patent product. Daqing biology has more than 300 high-tech talents composed of experts, professors, doctors and masters. Through the establishment of a scientific human resources assessment system, the establishment of employee stock holding platform, the establishment and implementation of ERP information management system, the company has established a people-oriented talent concept and built an excellent corporate culture. The company pays attention to the cultivation of employees' ability and quality. In order to improve the management ability of the core team, in 2013 and 2016, it cooperated with Guanghua School of management, Peking University, and specially set up the first and second classes of EMBA advanced studies.

本文链接: https://www.waitui.com/brand/eddd09692.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

上海市副市长陈杰:加快建设人工智能“上海高地”,壮大开源社区力量

36氪获悉,2月23日,2025全球开发者先锋大会在上海徐汇召开,上海市副市长陈杰出席开幕式并发表致辞。陈杰指出,面对人工智能快速迭代、模型开源的新趋势,上海将继续发挥超大城市的综合优势,加快建设更具国际影响力的人工智能“上海高地”。进一步完善开源开放生态系统,夯实“语料开放+模型开源”服务体系,不断壮大开源社区力量,推动基础模型、算法和数据资源的共享与开放,构建开放协作、互利共赢的创新环境。(中国基金报)

31分钟前

清华AIR联合水木分子开源DeepSeek版多模态生物医药大模型BioMedGPT-R1

36氪获悉,清华大学人工智能产业研究院(AIR)和北京水木分子生物科技有限公司近日携手推出了升级版的生物医药多模态开源基础大模型BioMedGPT-R1。此前,在2023年,双方合作发布了开源可商用、生物医药多模态百亿参数开源基础大模型BioMedGPT,水木分子发布了自研千亿参数多模态生物医药专业大模型Chat DD-FM和新一代AI驱动药物发现工具Chat DD。这次DeepSeek版ChatDD- R1基座模型也已同步上线ChatDD,赋能生物医药企业的药物研发。

31分钟前

TCL李东生:中国制造未来在海外最大增量大概率来自新兴市场

36氪获悉,TCL&奥林匹克全球合作伙伴签约仪式近日在北京举行。会后,TCL创始人、董事长李东生接受记者采访时表示,当前全球产业链面临转移与重构,持续由全球化向区域化、本土化方向发展。中国制造未来在海外最大的增量空间大概率来自新兴市场,比如巴西等新兴经济体。目前TCL海外制造基地分布在越南、马来西亚、菲律宾、印尼、印度、巴基斯坦、波兰、墨西哥、巴西等九个国家,实现东南亚、南亚、欧洲、北美、南美等各大区域本土化制造布局。未来,会持续关注新兴市场的增长潜力。

31分钟前

深圳:来深毕业生免费7天住升级为15天

为方便各地高校毕业生来深找工作,深圳相继推出“青年驿站”“深梦启航”“深梦扬帆”等“深梦”系列公益活动,为各地来深高校毕业生提供免费7天居住福利,解决他们阶段性、过渡性的居住需求。 2月23日,深圳市政府新闻办召开“打造最好科技创新生态和人才发展环境”新闻发布会。市委科创委办公室主任、科技创新局局长张林在会上透露,深圳为高校应届毕业生来深求职提供免费住宿天数,将从7天延长到15天。 (深圳特区报)

31分钟前

湖南规范互联网医院处方行为:严禁使用AI等自动生成处方

36氪获悉,湖南省医保局近日发布《关于进一步加强基本医疗保障定点零售药店管理的通知》。通知中提到,规范互联网医院处方行为。对互联网医院处方有如下几个措施:①压实实体医疗机构责任。依托实体医疗机构与市级医保部门签订补充协议,强化实体医疗机构的管理责任,因互联网医院违规被解除补充协议的原则上同步解除实体医疗机构医保定点协议,依托的实体医疗机构原则上应为二级及以上医疗机构。②纳入医保管理范畴。在本统筹区提供处方服务的由本市医保中心签协议后公布,跨市州提供处方服务的先征得药店所在地市级医保中心同意,再报省医保中心审定公布。③接入处方流转平台。互联网医院须按规定接入省医保电子处方中心并进行电子处方流转。④明确处方要求。处方行为必须符合行业主管部门管理办法,应与患者或患者家属进行有效、充分的沟通问诊,严禁使用人工智能等自动生成处方。

31分钟前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询